IL17A and neoplasm: Data shown in Figures 7A and B (for 4THM and EMT6, respectively) showed a modestly increased migration only of EMT6 tumor cells in the presence of 4THM tumor‐bearer serum/exosomes and recombinant IL‐6 (not IL‐17), with attenuation of migration of both 4THM and EMT6 by anti‐IL‐6 in vitro.